Literature DB >> 1456083

Transcriptional activation of c-fos and c-jun protooncogenes by serum growth factors in osteoblast-like MC3T3-E1 cells.

R Okazaki1, K Ikeda, A Sakamoto, T Nakano, K Morimoto, T Kikuchi, K Urakawa, E Ogata, T Matsumoto.   

Abstract

The present study was undertaken to clarify the relationship between c-fos and c-jun protooncogene expression and the differentiation and/or proliferation of osteoblasts, using osteoblast-like MC3T3-E1 (E1) cells. c-fos mRNA was barely detectable, whereas c-jun mRNA was constitutively expressed in E1 cells after serum deprivation for 24-72 h. When serum was added, a rapid and transient induction of c-fos and c-jun mRNAs was observed. The c-fos and c-jun mRNAs reached peak levels at 30 minutes, with a rapid disappearance of c-fos mRNA within 3 h and a much slower decrease in c-jun mRNA. The addition of serum together with cycloheximide, an inhibitor of protein synthesis, resulted in the superinduction of both c-fos and c-jun mRNAs. Among various growth factors, PDGF, EGF, and bFGF mimicked the serum effect, whereas IGF-I and TGF-beta failed to induce c-fos and c-jun mRNA. The effects of PDGF, EGF, and bFGF were completely abolished by pretreatment with actinomycin D, an inhibitor of RNA synthesis, suggesting a transcriptional mechanism. Nuclear runoff experiments showed that the transcription rate of c-fos and c-jun protooncogenes was increased by serum and growth factors. The effects of PDGF, EGF, and bFGF were inhibited by H-7 or staurosporine, inhibitors of protein kinase C (PKC), but not by HA1004 with a much weaker inhibitory activity, suggesting the involvement of PKC for the activation of the protooncogenes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456083     DOI: 10.1002/jbmr.5650071006

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation.

Authors:  A Montero; Y Okada; M Tomita; M Ito; H Tsurukami; T Nakamura; T Doetschman; J D Coffin; M M Hurley
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Epidermal growth factor induces Egr-1 messenger RNA and protein in mouse osteoblastic cells.

Authors:  M A Fang; G M Noguchi; S McDougall
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

3.  The effects of the insulin-like growth factors and transforming growth factor beta on the Jun proto-oncogene family in MC3T3-E1 cells.

Authors:  D D Strong; H L Merriman; E C Landale; D J Baylink; S Mohan
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

4.  Differential effects of glucocorticoids on human osteoblastic cell metabolism in vitro.

Authors:  C Kasperk; U Schneider; U Sommer; F Niethard; R Ziegler
Journal:  Calcif Tissue Int       Date:  1995-08       Impact factor: 4.333

5.  Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor.

Authors:  H Kawaguchi; C C Pilbeam; G Gronowicz; C Abreu; B S Fletcher; H R Herschman; L G Raisz; M M Hurley
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

6.  The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts.

Authors:  Nadiya M Teplyuk; Larisa M Haupt; Ling Ling; Christian Dombrowski; Foong Kin Mun; Saminathan S Nathan; Jane B Lian; Janet L Stein; Gary S Stein; Simon M Cool; Andre J van Wijnen
Journal:  J Cell Biochem       Date:  2009-05-01       Impact factor: 4.429

7.  FGF2 Stimulates COUP-TFII Expression via the MEK1/2 Pathway to Inhibit Osteoblast Differentiation in C3H10T1/2 Cells.

Authors:  Mi Nam Lee; Jung-Woo Kim; Sin-Hye Oh; Byung-Chul Jeong; Yun-Chan Hwang; Jeong-Tae Koh
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.